{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:14:13Z","timestamp":1793654053768,"version":"4.5.1"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Bristol Myers Squibb"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To estimate prevalence, incidence and mortality rates, and annual healthcare costs of primary Sj\u00f6gren\u2019s syndrome (pSS) and SS associated with other autoimmune disorders (SS+AID) in France.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>French national healthcare claims-based study within the prospective Syst\u00e8me National des Donn\u00e9es de Sant\u00e9 database that includes the majority of the French population. An algorithm was developed to identify patients with SS and SS-related healthcare claims were analysed between 2011 and 2018.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 23 848 patients with pSS and 14 809 with SS+AID were identified. From 2011 to 2018, the prevalence rate increased slightly for pSS (23\u201332 per 100000) and SS+AID (16\u201320 per 100 000), with females comprising 90%\u201391% and 92%\u201393% of cases, respectively. The incidence rate of SS per 100 000 persons decreased from 2012 (pSS: 4.3; SS+AID: 2.0) to 2017 (pSS: 0.7; SS+AID: 0.3). Mortality rates per 100 000 persons increased from 2012 to 2018 in patients with pSS (0.2\u20130.8) or SS+AID (0.1\u20130.5); mean age of death also increased. Artificial tears and hydroxychloroquine were the most common drug reimbursements. Less than half of patients received annual specialist care from a dentist or ophthalmologist. Healthcare costs associated with SS increased from 2011 to 2018 and exceeded the national estimate of expected costs for chronic diseases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large French population database study, the low prevalence of pSS confirms that it is an orphan disease. SS is clinically and economically burdensome; these findings may help clinicians better understand routine healthcare received by patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003591","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T13:07:22Z","timestamp":1706879242000},"page":"e003591","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Estimated prevalence, incidence and healthcare costs of Sj\u00f6gren\u2019s syndrome in France: a national claims-based study"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5523-1856","authenticated-orcid":false,"given":"Raphaele","family":"Seror","sequence":"first","affiliation":[{"name":"Department of Rheumatology, INSERM U1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Bic\u00eatre, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Chiche","sequence":"additional","affiliation":[{"name":"Unit\u00e9 de Medicine Interne et Recherche Clinique, H\u00f4pital Europ\u00e9en Marseille, Marseille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4924-093X","authenticated-orcid":false,"given":"Maxime","family":"Beydon","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, INSERM U1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Bic\u00eatre, Universit\u00e9 Paris-Saclay, Le Kremlin-Bic\u00eatre, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Desjeux","sequence":"additional","affiliation":[{"name":"e-Health Services Sanoia SASU, Aubagne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Zhuo","sequence":"additional","affiliation":[{"name":"Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Vannier-Moreau","sequence":"additional","affiliation":[{"name":"Medical Affairs, Bristol Myers Squibb Research & Development Rueil-Malmaison, Rueil Malmaison, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Devauchelle-Pensec","sequence":"additional","affiliation":[{"name":"Rheumatology Department, CHU de Cavale Blanche, Brest, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"2025090313421427000_10.1.e003591.1","doi-asserted-by":"crossref","unstructured":"Beydon M , McCoy S , Nguyen Y , et al . Epidemiology of Sj\u00f6gren syndrome. Nat Rev Rheumatol 2023. doi:10.1038\/s41584-023-01057-6","DOI":"10.1038\/s41584-023-01057-6"},{"key":"2025090313421427000_10.1.e003591.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1702514"},{"key":"2025090313421427000_10.1.e003591.3","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.22115","article-title":"Epidemiology of primary Sjogren\u2019s syndrome in a French Multiracial\/Multiethnic area","volume":"66","author":"Maldini","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313421427000_10.1.e003591.4","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00728-6"},{"key":"2025090313421427000_10.1.e003591.5","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jbspin.2015.10.005","article-title":"Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjogren\u2019s syndrome","volume":"83","author":"Milin","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090313421427000_10.1.e003591.6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202863"},{"key":"2025090313421427000_10.1.e003591.7","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/rheumatology\/kez578","article-title":"Epidemiological profile and North-South gradient driving baseline systemic involvement of primary Sjogren\u2019s syndrome","volume":"59","author":"Brito-Zer\u00f3n","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313421427000_10.1.e003591.8","first-page":"97","article-title":"Systemic manifestations of primary Sjogren\u2019s syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large International, multi-ethnic cohort of patients","volume":"37 Suppl 118","author":"Retamozo","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313421427000_10.1.e003591.9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318181e6af"},{"key":"2025090313421427000_10.1.e003591.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059868","article-title":"Serum levels of Beta2-Microglobulin and free light chains of Immunoglobulins are associated with systemic disease activity in primary Sjogren\u2019s syndrome. data at enrollment in the prospective ASSESS cohort","volume":"8","author":"Gottenberg","year":"2013","journal-title":"PLoS One"},{"key":"2025090313421427000_10.1.e003591.11","doi-asserted-by":"crossref","first-page":"166","DOI":"10.55563\/clinexprheumatol\/egnd1i","article-title":"Influence of the age at diagnosis in the disease expression of primary Sjogren syndrome. analysis of 12,753 patients from the Sjogren big data consortium","volume":"39 Suppl 133","author":"Retamozo","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"2025090313421427000_10.1.e003591.12","doi-asserted-by":"crossref","first-page":"105132","DOI":"10.1016\/j.jbspin.2021.105132","article-title":"Elderly-onset primary Sjogren\u2019s syndrome focused on clinical and salivary gland ultrasonographic features","volume":"88","author":"Lee","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2025090313421427000_10.1.e003591.13","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.676885","article-title":"Management of Sjogren\u2019s syndrome: present issues and future perspectives","volume":"8","author":"Vitali","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"2025090313421427000_10.1.e003591.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205375"},{"key":"2025090313421427000_10.1.e003591.15","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/14397595.2013.843765","article-title":"Primary and secondary surveys on epidemiology of Sjogren\u2019s syndrome in Japan","volume":"24","author":"Tsuboi","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2025090313421427000_10.1.e003591.16","doi-asserted-by":"crossref","first-page":"16047","DOI":"10.1038\/nrdp.2016.47","article-title":"Sjogren syndrome","volume":"2","author":"Brito-Zer\u00f3n","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2025090313421427000_10.1.e003591.17","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2014-206860","article-title":"Is primary Sjogren\u2019s syndrome an orphan disease? A critical appraisal of prevalence studies in Europe","volume":"74","author":"Cornec","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2025090313421427000_10.1.e003591.18","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of primary Sjogren syndrome with Rituximab: a randomized trial","volume":"160","author":"Devauchelle-Pensec","year":"2014","journal-title":"Ann Intern Med"},{"key":"2025090313421427000_10.1.e003591.19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/art.40513","article-title":"Clinical efficacy and safety of Baminercept, a Lymphotoxin beta receptor fusion protein, in primary Sjogren\u2019s syndrome: results from a phase II randomized, double-blind, placebo-controlled trial","volume":"70","author":"St Clair","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090313421427000_10.1.e003591.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218467"},{"key":"2025090313421427000_10.1.e003591.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-218599"},{"key":"2025090313421427000_10.1.e003591.22","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral Seletalisib in primary Sjogren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313421427000_10.1.e003591.23","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2665-9913(19)30135-3","article-title":"Assessment of the anti-Cd40 antibody Iscalimab in patients with primary Sj\u00f6gren\u2019s syndrome: a Multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study","volume":"2","author":"Fisher","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025090313421427000_10.1.e003591.24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(21)02251-0","article-title":"Safety and efficacy of subcutaneous Ianalumab (Vay736) in patients with primary Sjogren\u2019s syndrome: a randomised, double-blind, placebo-controlled, phase 2B dose-finding trial","volume":"399","author":"Bowman","year":"2022","journal-title":"Lancet"},{"key":"2025090313421427000_10.1.e003591.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.110619"},{"key":"2025090313421427000_10.1.e003591.26","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S2665-9913(20)30057-6","article-title":"Leflunomide\u2013hydroxychloroquine combination therapy in patients with primary Sj\u00f6gren\u2019s syndrome (Repurpss-I): a placebo-controlled, double-blinded, randomised clinical trial","volume":"2","author":"van der Heijden","year":"2020","journal-title":"The Lancet Rheumatology"},{"key":"2025090313421427000_10.1.e003591.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216114"},{"key":"2025090313421427000_10.1.e003591.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2010.04.005"},{"key":"2025090313421427000_10.1.e003591.29","unstructured":"Devauchelle-Pensec v , Zhuo J , Lavrard I , et al . Development of an algorithm to identify Sj\u00f6gren\u2019s syndrome patients in the French National Healthcare claims database. Arthritis Rheumatol 2019:1101."},{"key":"2025090313421427000_10.1.e003591.30","unstructured":"Maladie A . [online]. 2019]. Am\u00e9liorer la qualit\u00e9 du syst\u00e8me de sant\u00e9 et ma\u00eetriser les d\u00e9penses, Available: https:\/\/assurance-maladie.ameli.fr\/sites\/default\/files\/rapport-charges-et-produits-2019-web.pdf [Accessed 29 Jun 2021]."},{"key":"2025090313421427000_10.1.e003591.31","unstructured":"Gougerot-Sj\u00f6gren . Fili\u00e8re de Sant\u00e9 des maladies auto-Immunes et auto-Inflammatoires Rares. 2017. Available: https:\/\/www.fai2r.org\/les-pathologies-rares\/gougerot-sjogren\/"},{"key":"2025090313421427000_10.1.e003591.32","unstructured":"ERN reconnect . Sj\u00f6gren\u2019s syndrome, . 2018 Available: https:\/\/reconnet.ern-net.eu\/disease_ss\/ [Accessed 15 Feb 2023]."},{"key":"2025090313421427000_10.1.e003591.33","unstructured":"Devauchelle V , Mariette X , Benyoussef A-A , et al . Maladie (ou syndrome) de Sj\u00f6gren, . 2022 Available: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-03\/pnds_sjogren_mars_2022.pdf [Accessed 15 Feb 2023]."},{"key":"2025090313421427000_10.1.e003591.34","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/joim.12992","article-title":"Weight of salivary gland Ultrasonography compared to other items of the 2016 ACR\/EULAR classification criteria for primary Sjogren\u2019s syndrome","volume":"287","author":"Jousse-Joulin","year":"2020","journal-title":"J Intern Med"},{"key":"2025090313421427000_10.1.e003591.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev354"},{"key":"2025090313421427000_10.1.e003591.36","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/rheumatology\/keaa009","article-title":"Equal rights in Autoimmunity: is Sjogren\u2019s syndrome ever \u2019secondary","volume":"59","author":"Kollert","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2025090313421427000_10.1.e003591.37","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1007\/s10067-020-05004-8","article-title":"Prevalence of Sjogren\u2019s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona Registry","volume":"39","author":"Harrold","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025090313421427000_10.1.e003591.38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/03009742.2017.1324909","article-title":"Systematic review and meta-analysis of the epidemiology of Polyautoimmunity in Sjogren\u2019s syndrome (secondary Sjogren\u2019s syndrome) focusing on autoimmune rheumatic diseases","volume":"47","author":"Alani","year":"2018","journal-title":"Scandinavian Journal of Rheumatology"},{"key":"2025090313421427000_10.1.e003591.39","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.9.897"},{"key":"2025090313421427000_10.1.e003591.40","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.7.415"},{"key":"2025090313421427000_10.1.e003591.41","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu400"},{"key":"2025090313421427000_10.1.e003591.42","first-page":"1098","article-title":"Secondary Sjogren\u2019s syndrome in rheumatoid arthritis","volume":"14","author":"Andonopoulos","year":"1987","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"2025090313421427000_10.1.e003591.43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00393-021-01051-x","article-title":"Polyautoimmunity in systemic lupus erythematosus: secondary Sjogren syndrome","volume":"82","author":"Sieiro Santos","year":"2023","journal-title":"Z Rheumatol"},{"key":"2025090313421427000_10.1.e003591.44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jbspin.2015.05.010","article-title":"Characteristics and management of rheumatoid arthritis in France: analysis of a representative French national claims database resulting in an estimated prevalence of 0.35","volume":"83","author":"Fautrel","year":"2016","journal-title":"Joint Bone Spine"},{"key":"2025090313421427000_10.1.e003591.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.20093"},{"key":"2025090313421427000_10.1.e003591.46","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s40744-021-00314-y","article-title":"Primary Sjogren\u2019s syndrome: a retrospective cohort study of burden of illness in Sweden","volume":"8","author":"Westerlund","year":"2021","journal-title":"Rheumatol Ther"},{"key":"2025090313421427000_10.1.e003591.47","unstructured":"Statista . Inflation rates in France from 2004 to 2022, . 2023 Available: https:\/\/fr.statista.com\/statistiques\/479759\/taux-inflation-france\/ [Accessed 24 Oct 2023]."},{"key":"2025090313421427000_10.1.e003591.48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.78"},{"key":"2025090313421427000_10.1.e003591.49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40744-023-00611-8","article-title":"Epidemiology of Sj\u00f6gren\u2019s: A Systematic Literature Review","volume":"11","author":"Thurtle","year":"2024","journal-title":"Rheumatol Ther"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:42:28Z","timestamp":1756932148000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2,2]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/rmdopen-2023-003591"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003591","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}